• Je něco špatně v tomto záznamu ?

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

M. Ogura, JM. Sancho, SG. Cho, H. Nakazawa, J. Suzumiya, G. Tumyan, JS. Kim, A. Lennard, J. Mariz, N. Ilyin, W. Jurczak, A. Lopez Martinez, O. Samoilova, E. Zhavrid, E. Yañez Ruiz, M. Trneny, L. Popplewell, B. Coiffier, C. Buske, WS. Kim, SJ....

. 2018 ; 5 (11) : e543-e553.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000270

BACKGROUND: Studies in patients with rheumatoid arthritis and advanced follicular lymphoma have shown that CT-P10, a rituximab biosimilar, has equivalent or non-inferior efficacy and pharmacokinetics to rituximab. We aimed to assess the therapeutic equivalence of single-agent CT-P10 and rituximab in patients with newly diagnosed low-tumour burden follicular lymphoma. METHODS: In this ongoing, randomised, double-blind, parallel-group, active-controlled, phase 3 trial, adult patients (≥18 years) with stage II-IV low-tumour-burden follicular lymphoma were randomly assigned (1:1) using an interactive web or voice response system stratified by region, stage, and age to CT-P10 or US-sourced rituximab. Patients received CT-P10 or rituximab (375 mg/m2 intravenous) on day 1 of four 7-day cycles (induction period). Patients who had disease control after the induction period continued to a maintenance period of CT-P10 or rituximab administered every 8 weeks for six cycles and, if completed, a second year of maintenance therapy of additional CT-P10 (every 8 weeks for six cycles) was offered. The study was partially unmasked after database lock (Feb 23, 2018) for all data up to 7 months (before cycle 3 of the maintenance period). The primary endpoint was the proportion of patients who achieved an overall response by 7 months in the intention-to-treat population. Efficacy equivalence was shown if the two-sided 90% CIs for the treatment difference in the proportion of responders between CT-P10 and rituximab was within the equivalence margin of 17%. This trial is registered with ClinicalTrials.gov, number NCT02260804. FINDINGS: Between Nov 9, 2015, and Jan 4, 2018, 402 patients were assessed for eligibility, of whom 258 were randomly assigned: 130 to CT-P10 and 128 to rituximab. 108 (83%) of 130 patients assigned to CT-P10 and 104 (81%) of 128 assigned to rituximab achieved an overall response by month 7 (treatment difference estimate 1·8%; 90% CI -6·43 to 10·20). Therapeutic equivalence was shown (90% CIs were within the prespecified margin of 17%). The most common grade 3 or 4 treatment-emergent adverse events were decreased neutrophil count (two grade 3 in the CT-P10 group) and neutropenia (one in each group); all other grade 3 or 4 treatment-emergent adverse events occurred in one patient each. Six (5%) of 130 patients who received CT-P10 and three (2%) of 128 who received rituximab experienced at least one treatment-emergent serious adverse event. INTERPRETATION: CT-P10 was equivalent to rituximab in terms of efficacy and was well tolerated. CT-P10 monotherapy is suggested as a new therapeutic option for patients with low-tumour-burden follicular lymphoma. FUNDING: Celltrion, Inc.

Celltrion Inc Incheon South Korea

Comprehensive Cancer Center Ulm University Hospital of Ulm Ulm Germany

Department of Haematology and Oncology Kasugai Municipal Hospital Kasugai Japan

Department of Haematology Jagiellonian University Kraków Poland

Department of Hematology Catholic Blood and Marrow Transplantation Center Seoul St Mary's Hospital The Catholic University of Korea Seoul South Korea

Department of Hematology Hospices Civils de Lyon Lyon France

Department of Hematology Hospital Arnau de Vilanova Valencia Spain

Department of Hematology Nizhniy Novgorod Region Clinical Hospital Nizhniy Novgorod Russia

Department of Hematology Shinshu University School of Medicine Matsumoto Japan

Department of Internal Medicine Universidad de la Frontera Temuco Chile

Department of Internal Medicine Yonsei University College of Medicine Severance Hospital Seoul South Korea

Department of Medicine Charles University General Hospital Prague Prague Czech Republic

Department of Onco Hematology Portuguese Institute of Oncology Porto Portugal

Division of Hematology and Bone Marrow Transplantation N N Blokhin Russian Cancer Research Center Moscow Russia

Division of Hematology and Oncology Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea

Hematology Department The Catalan Institute of Oncology The Josep Carreras Leukaemia Research Institute Hospital Germans Trias i Pujol Badalona Spain

N N Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology Minsk Belarus

Northern Institute for Cancer Care Newcastle University Newcastle upon Tyne UK

Russian Research Center for Radiology and Surgical Technologies Ministry of Health of the Russian Federation St Petersburg Russia

School of Medicine Fujita Medical University Toyoake Japan

Shimane University Hospital Innovative Cancer Center Oncology Hematology Izumo Japan

Toni Stephenson Lymphoma Center and Department of Hematology and Hematopoietic Cell Transplantation City of Hope Duarte CA USA

000      
00000naa a2200000 a 4500
001      
bmc19000270
003      
CZ-PrNML
005      
20240313101336.0
007      
ta
008      
190107s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S2352-3026(18)30157-1 $2 doi
035    __
$a (PubMed)30389036
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ogura, Michinori $u Department of Haematology and Oncology, Kasugai Municipal Hospital, Kasugai, Japan; School of Medicine, Fujita Medical University, Toyoake, Japan.
245    10
$a Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial / $c M. Ogura, JM. Sancho, SG. Cho, H. Nakazawa, J. Suzumiya, G. Tumyan, JS. Kim, A. Lennard, J. Mariz, N. Ilyin, W. Jurczak, A. Lopez Martinez, O. Samoilova, E. Zhavrid, E. Yañez Ruiz, M. Trneny, L. Popplewell, B. Coiffier, C. Buske, WS. Kim, SJ. Lee, SY. Lee, YJ. Bae, LW. Kwak,
520    9_
$a BACKGROUND: Studies in patients with rheumatoid arthritis and advanced follicular lymphoma have shown that CT-P10, a rituximab biosimilar, has equivalent or non-inferior efficacy and pharmacokinetics to rituximab. We aimed to assess the therapeutic equivalence of single-agent CT-P10 and rituximab in patients with newly diagnosed low-tumour burden follicular lymphoma. METHODS: In this ongoing, randomised, double-blind, parallel-group, active-controlled, phase 3 trial, adult patients (≥18 years) with stage II-IV low-tumour-burden follicular lymphoma were randomly assigned (1:1) using an interactive web or voice response system stratified by region, stage, and age to CT-P10 or US-sourced rituximab. Patients received CT-P10 or rituximab (375 mg/m2 intravenous) on day 1 of four 7-day cycles (induction period). Patients who had disease control after the induction period continued to a maintenance period of CT-P10 or rituximab administered every 8 weeks for six cycles and, if completed, a second year of maintenance therapy of additional CT-P10 (every 8 weeks for six cycles) was offered. The study was partially unmasked after database lock (Feb 23, 2018) for all data up to 7 months (before cycle 3 of the maintenance period). The primary endpoint was the proportion of patients who achieved an overall response by 7 months in the intention-to-treat population. Efficacy equivalence was shown if the two-sided 90% CIs for the treatment difference in the proportion of responders between CT-P10 and rituximab was within the equivalence margin of 17%. This trial is registered with ClinicalTrials.gov, number NCT02260804. FINDINGS: Between Nov 9, 2015, and Jan 4, 2018, 402 patients were assessed for eligibility, of whom 258 were randomly assigned: 130 to CT-P10 and 128 to rituximab. 108 (83%) of 130 patients assigned to CT-P10 and 104 (81%) of 128 assigned to rituximab achieved an overall response by month 7 (treatment difference estimate 1·8%; 90% CI -6·43 to 10·20). Therapeutic equivalence was shown (90% CIs were within the prespecified margin of 17%). The most common grade 3 or 4 treatment-emergent adverse events were decreased neutrophil count (two grade 3 in the CT-P10 group) and neutropenia (one in each group); all other grade 3 or 4 treatment-emergent adverse events occurred in one patient each. Six (5%) of 130 patients who received CT-P10 and three (2%) of 128 who received rituximab experienced at least one treatment-emergent serious adverse event. INTERPRETATION: CT-P10 was equivalent to rituximab in terms of efficacy and was well tolerated. CT-P10 monotherapy is suggested as a new therapeutic option for patients with low-tumour-burden follicular lymphoma. FUNDING: Celltrion, Inc.
650    _2
$a myší monoklonální protilátky $x škodlivé účinky $x farmakokinetika $x farmakologie $x terapeutické užití $7 D058846
650    _2
$a biosimilární léčivé přípravky $x škodlivé účinky $x farmakokinetika $x farmakologie $x terapeutické užití $7 D059451
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a folikulární lymfom $x farmakoterapie $x metabolismus $x patologie $7 D008224
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a rituximab $x škodlivé účinky $x farmakokinetika $x farmakologie $x terapeutické užití $7 D000069283
650    12
$a bezpečnost $7 D012449
650    _2
$a výsledek terapie $7 D016896
650    12
$a tumor burden $x účinky léků $7 D047368
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Sancho, Juan Manuel $u Hematology Department, The Catalan Institute of Oncology-The Josep Carreras Leukaemia Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain.
700    1_
$a Cho, Seok-Goo $u Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
700    1_
$a Nakazawa, Hideyuki $u Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan.
700    1_
$a Suzumiya, Junji $u Shimane University Hospital, Innovative Cancer Center/Oncology-Hematology, Izumo, Japan.
700    1_
$a Tumyan, Gayane $u Division of Hematology and Bone Marrow Transplantation, N N Blokhin Russian Cancer Research Center, Moscow, Russia.
700    1_
$a Kim, Jin Seok $u Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea.
700    1_
$a Lennard, Anne $u Northern Institute for Cancer Care, Newcastle University, Newcastle-upon-Tyne, UK.
700    1_
$a Mariz, José $u Department of Onco-Hematology, Portuguese Institute of Oncology, Porto, Portugal.
700    1_
$a Ilyin, Nikolai $u Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, St Petersburg, Russia.
700    1_
$a Jurczak, Wojciech $u Department of Haematology, Jagiellonian University, Kraków, Poland.
700    1_
$a Lopez Martinez, Aurelio $u Department of Hematology, Hospital Arnau de Vilanova, Valencia, Spain.
700    1_
$a Samoilova, Olga $u Department of Hematology, Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russia.
700    1_
$a Zhavrid, Edvard $u N N Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Minsk, Belarus.
700    1_
$a Yañez Ruiz, Eduardo $u Department of Internal Medicine, Universidad de la Frontera, Temuco, Chile.
700    1_
$a Trneny, Marek $u Department of Medicine, Charles University, General Hospital in Prague, Prague, Czech Republic.
700    1_
$a Popplewell, Leslie $u Toni Stephenson Lymphoma Center and Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
700    1_
$a Coiffier, Bertrand, $d 1947-2019 $u Department of Hematology, Hospices Civils de Lyon, Lyon, France. $7 xx0314848
700    1_
$a Buske, Christian $u Comprehensive Cancer Center Ulm, University Hospital of Ulm, Ulm, Germany.
700    1_
$a Kim, Won-Seog $u Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
700    1_
$a Lee, Sang Joon $u Celltrion, Inc., Incheon, South Korea.
700    1_
$a Lee, Sung Young $u Celltrion, Inc., Incheon, South Korea.
700    1_
$a Bae, Yun Ju $u Celltrion, Inc., Incheon, South Korea.
700    1_
$a Kwak, Larry W $u Toni Stephenson Lymphoma Center and Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA. Electronic address: lkwak@fsm.northwestern.edu.
773    0_
$w MED00193479 $t The Lancet. Haematology $x 2352-3026 $g Roč. 5, č. 11 (2018), s. e543-e553
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30389036 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20240313101332 $b ABA008
999    __
$a ok $b bmc $g 1364386 $s 1038393
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 5 $c 11 $d e543-e553 $i 2352-3026 $m The Lancet. Haematology $n Lancet Haematol $x MED00193479
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace